Business Context and Reporting Period
This Form 8-K Current Report from Praxis Precision Medicines, Inc. (PRAX) covers events occurring on December 4, 2025, and December 6, 2025. The filing details significant clinical and regulatory milestones for the Company's pipeline, specifically regarding ulixacaltamide, relutrigine, and vormatrigine.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory interactions rather than financial performance.
Material Changes and Clinical Results
Ulixacaltamide
- Successfully completed the pre-New Drug Application (NDA) meeting with the FDA on December 4, 2025.
- Received written feedback and achieved alignment on NDA content.
- Expects to submit the NDA in early 2026.
Relutrigine (EM_BOLD Study)
- Data Monitoring Committee recommended stopping the registrational cohort study early for efficacy.
- Seizure Reduction: 53% placebo-adjusted reduction over 16 weeks (p<0.0002).
- Seizure-Free Days: 66% increase in motor seizure-free days (p=0.034).
- Functional Improvements: Statistically significant improvements in alertness, communication, and seizure severity.
- Safety: No drug-related serious adverse events; treatment-related adverse events were predominantly mild to moderate.
- Company will meet with the FDA in the coming weeks to discuss next steps and determine NDA filing timing.
Vormatrigine (RADIANT Study)
- Focal Onset Seizures (n=62): 54% median reduction in seizures over 8 weeks. 58% of patients achieved ≥50% reduction in week 1, increasing to 61% by week 8. Median weekly seizure reduction reached 100% after 8 weeks and was maintained through 16 weeks.
- Seizure Freedom: Over 11% of patients were seizure-free for the entire 8-week period; roughly one-third were seizure-free for a consecutive 28-day period.
- Generalized Epilepsy (n=3): Patients experienced rapid, durable seizure reduction similar to the FOS cohort.
Guidance, Outlook, and Risks
Development Timeline
- POWER1 (FOS): Recruitment completed.
- POWER2: On track to complete in the second half of 2026.
- POWER3 (Monotherapy): On track to begin in the first half of 2026.
Risks and Contingencies
The filing includes standard forward-looking statements cautioning that clinical development, regulatory submission timing, and approval are subject to uncertainties inherent in clinical trials and regulatory review. The Company undertakes no obligation to update these statements.
Investor Verification Checklist
- Confirm the specific date of the FDA meeting regarding relutrigine NDA next steps.
- Verify the exact timeline for the ulixacaltamide NDA submission in early 2026.
- Monitor the enrollment and data readout dates for the POWER2 and POWER3 studies.
- Review the full safety data for relutrigine and vormatrigine in the respective study reports.
- Check subsequent filings for the official NDA submission dates for ulixacaltamide and relutrigine.